Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

RecruitingRare disease

Study on the Effectiveness of Dutasteride with Goserelin Acetate and Bicalutamide in Patients with Recurrent or Metastatic Salivary Duct Carcinoma

Fast replyRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a type of cancer called Salivary Duct Carcinoma, which affects the salivary glands. The study is investigating the effectiveness of a treatment that combines a medication called Dutasteride with a therapy known as combined androgen blockade. This therapy involves using medications that block male hormones, which can help slow the growth of certain types of cancer. The medications used in this study include Dutasteride, Zoladex, and Casodex. Zoladex is administered as an implant under the skin, while Casodex is taken orally as a tablet.

The purpose of the study is to determine how effective the combination of Dutasteride and combined androgen blockade therapy is in treating patients with recurrent or metastatic Salivary Duct Carcinoma. The study will compare the outcomes of patients receiving the combination treatment to those receiving only the combined androgen blockade therapy. Some participants will receive a placebo instead of Dutasteride to help researchers understand the treatment's effects more clearly.

Participants in the study will receive treatment for a period of up to 12 months, with regular check-ups to monitor their health and the progress of the cancer. The study will also collect information on the overall response to the treatment, the duration of response, and any side effects experienced. The trial aims to provide valuable insights into the potential benefits of adding Dutasteride to the existing treatment regimen for this type of cancer.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial visit

    Upon joining the study, you will have an initial visit with the clinical trial team. During this visit, your medical history will be reviewed, and you will undergo a physical examination. Blood tests and imaging studies may be conducted to assess your current health status and the extent of your salivary duct carcinoma.

  2. Step 2

    Treatment assignment

    You will be randomly assigned to one of two treatment groups. One group will receive a combination of goserelin acetate, bicalutamide, and dutasteride, while the other group will receive only goserelin acetate and bicalutamide. This process is called randomization and ensures that the study results are unbiased.

  3. Step 3

    Medication administration

    If you are in the group receiving all three medications, you will receive a goserelin acetate implant (10.8 mg) as a subcutaneous injection every 12 weeks. You will also take bicalutamide tablets (50 mg) orally once a day and dutasteride capsules (0.5 mg) orally once a day.

    If you are in the group receiving only goserelin acetate and bicalutamide, you will follow the same schedule for these two medications without taking dutasteride.

  4. Step 4

    Regular follow-up visits

    You will have regular follow-up visits with the clinical trial team. These visits will occur at specified intervals to monitor your response to the treatment and to check for any side effects. Blood tests, imaging studies, and other assessments may be conducted during these visits.

  5. Step 5

    Quality of life assessments

    Throughout the trial, you will be asked to complete questionnaires about your quality of life. These assessments help the research team understand how the treatment affects your daily life and well-being.

  6. Step 6

    End of treatment

    At the end of the treatment period, you will have a final visit with the clinical trial team. Your overall health and response to the treatment will be evaluated. You may undergo additional tests and assessments as part of this final evaluation.

Who can join the trial?

10 criteria

  • Must have a confirmed diagnosis of **salivary duct carcinoma** that cannot be cured.
  • Must have **adequate heart function**.
  • The disease must be **AR positive**, meaning there is a strong presence of androgen receptors in at least 1% of the cancer cells.
  • Must have a **measurable disease** according to specific medical guidelines.
  • Must be **18 years or older**.
  • Must provide **written informed consent** as required by local laws.
  • Must have an **ECOG performance status** of 0 or 1, which means being fully active or having some symptoms but still able to carry out light work.
  • Must have **adequate bone marrow function**, which includes having enough white blood cells, neutrophils, hemoglobin, and platelets.
  • Must have **adequate liver function**, with specific limits on liver enzymes and bilirubin levels.
  • Must have **adequate kidney function**, with specific limits on creatinine levels or a certain level of kidney filtration rate.

Who cannot join the trial?

3 criteria

  • Patients who are not diagnosed with Salivary Duct Carcinoma cannot participate.
  • Patients who are under 18 years old cannot participate.
  • Patients who are part of a vulnerable population, such as those unable to give consent, cannot participate.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Dutasteride

    is a medication that is being tested in this trial to see if it can help treat salivary duct carcinoma, a type of cancer. It works by blocking certain hormones in the body that can help cancer cells grow. In this study, researchers want to find out if adding dutasteride to the usual cancer treatment can improve outcomes for patients with this type of cancer.

  • Combined Androgen Blockade Therapy

    is a standard treatment for certain types of cancer, including salivary duct carcinoma. This therapy works by reducing the levels of male hormones, which can help slow down or stop the growth of cancer cells. In this trial, combined androgen blockade therapy is used as a base treatment, and researchers are testing whether adding another medication, dutasteride, can make it more effective.

What is already known about the treatment

Dutasteride – Dutasteride is administered orally in the form of a capsule. It is currently being studied in clinical trials for its potential use in treating salivary duct carcinoma, a type of cancer affecting the salivary glands. The main therapeutic indication being explored is its effectiveness when combined with other therapies to manage recurrent or metastatic forms of this cancer. At the molecular level, dutasteride works by inhibiting the action of certain enzymes that convert testosterone into a more potent form, which can help slow the growth of cancer cells. It is classified pharmacologically as a 5-alpha-reductase inhibitor.

Investigated diseases

Salivary Duct Carcinoma – Salivary duct carcinoma is a rare and aggressive type of cancer that originates in the ducts of the salivary glands. It typically begins as a small, painless lump in the mouth or neck area. As the disease progresses, the tumor may grow rapidly and invade surrounding tissues, leading to symptoms such as pain, difficulty swallowing, or facial nerve dysfunction. The cancer cells can spread to nearby lymph nodes and other parts of the body, including the lungs and bones. This type of carcinoma is known for its potential to recur after initial treatment. The progression of the disease can vary, with some cases remaining localized while others become more widespread.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IVTrial ID2022-500745-24-00Estimated enrolment26 patientsSponsorStichting Radboud universitair medisch centrum

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).